BAM Logo

General Pathology

[General Pathology]

EPTIS factsheet 588739 | Last revision 2019-07-22 | URL: https://www.eptis.bam.de/pts588739 https://www.eptis.bam.de/pts588739

PT provider
PT provider UK NEQAS for Immunocytochemistry & In-Situ Hybridisation UK NEQAS for Immunocytochemistry & In-Situ Hybridisation
Based in United Kingdom
Language(s) English
Product groups Human test material
Testing fields Medical analysis
Technical details
Test item Tested property Testing method
FFPE sections of human tissues (normal and pathological) Diagnostic markers Immunocytochemistry
Aims of the PT scheme
Target group of participants Clinical and research cellular pathology laboratories (no geographical restrictions)
Linked to specific legislation / standards Accredited to ISO 17043:2010
Additional, subsidiary aims
Number of participants 300
Accredited or otherwise reviewed by a 3rd party

Accredited by UKAS on the basis of ISO 17043:2010

Operation is commissioned / requested by
Fees and frequency
Participation fee On application
Regularly operated Yes (Four distributions per year)
Year of first operation 1984
Contact details of the PT provider
Provider Contact person
UK NEQAS for Immunocytochemistry & In-Situ Hybridisation
Office 127, Finsbury Business Centre, 40 Bowling Green Lane
London EC1R 0NE
United Kingdom

Phone: +44 (0) 207 415 7065
Fax: +44 (0) 2017 415 7048
Web: https://www.ukneqasiccish.org/ https://www.ukneqasiccish.org/
MS Lin Rhodes
Phone: +44 (0) 207 415 7065
Email: info@ukneqasiccish.org info@ukneqasiccish.org
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom, Mr Savvas Xystouris. Mr Savvas Xystouris.
Any questions or problems? Please contact us at eptis@bam.de.
Application version: 1.23-SNAPSHOT.20230502124635-7925ae379a631fc1ececff45d2921c8db38877d5